000 03746nam a22003615i 4500
001 282855
003 MX-SnUAN
005 20160429154209.0
007 cr nn 008mamaa
008 150903s2008 ne | o |||| 0|eng d
020 _a9781402066863
_99781402066863
024 7 _a10.1007/9781402066863
_2doi
035 _avtls000335722
039 9 _a201509030240
_bVLOAD
_c201404300306
_dVLOAD
_y201402041307
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aR-RZ
100 1 _aSchulkin, Jay.
_eautor
_9309919
245 1 0 _aMedical Decisions, Estrogen and Aging /
_cby Jay Schulkin.
264 1 _aDordrecht :
_bSpringer Netherlands,
_c2008.
300 _brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
500 _aSpringer eBooks
505 0 _aHormone Therapy: Biological, Social, and Medical Context -- Demythologized Human Decision-Making -- Autonomic Regulation, Heart, and Strokes -- Bad News—Good News: Cancers and Bone -- Brain, Mood, and Cognition -- Physicians' and Women's Responses to HT Findings: Implications for Continuous Learning and Self-Corrective Inquiry for Physicians.
520 _aThe decision-making process that underlies ovarian hormone therapy (HT) is a fallible one. The question is whether or not physicians should prescribe HT to menopausal women, who are at a time in their lives when they are factoring various concerns into their decision to take (or not take) HT. Not only is it difficult to determine whether or not to prescribe HT, but what kind; should physicians recommend estrogen or progestin, or another combination of related hormones? The decision of whether or not to use HT has affected, and will continue to affect, many women in the United States and throughout the world and is an important model elucidating the forces that influence medical decision-making. Two recent large-scale studies, one conducted here in the United States (the Women’s Health Initiative) and the other in Great Britain (the Million Women Study), were highly publicized and cast a negative light on the use of HT. Since HT’s inception, views have oscillated, due in part to expectations of benefits extending over the course of long-term use beyond the peri-menopausal period, and perhaps due to the overselling of research investigating the efficacy of HT. Thus, the decision for women to go on HT remains a controversial issue, and the decision-making process is undermined further by overzealous advertising and an exaggerated understanding of the research results (both positive and negative). This book is unique in that it integrates core findings from within the Decision Sciences and Evidence Based Medicine in light of the research that has been done on HT. Medical Decisions, Estrogen and Aging integrates the various components that go into medical decision making in the context of understanding the dilemmas that surround HT. Therefore this book is intended for both specialists and generalists in the field, and it is ideally suited for use by graduate and medical students, medical health care professionals, behavioral scientists, medical ethicists, gerontologists, historians of science, and endocrinologists.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9781402066856
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4020-6686-3
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c282855
_d282855